Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.32 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25605598 | 0.89 | KDM4E (0.37) | KDM4EMEN1TSHRKMT2ACDK5 | |
| SCHEMBL20833449 | 0.80 | KDM4E (0.39) | KDM4EMEN1TSHRKMT2A | |
| SCHEMBL20833441 | 0.80 | KDM4E (0.39) | KDM4EMEN1TSHRKMT2A | |
| SCHEMBL22759957 | 0.79 | KDM4E (0.37) | KDM4EMEN1TSHRKMT2ACDK5 | |
| SCHEMBL13443499 | 0.75 | L3MBTL1 (0.36) | KDM4EMEN1TSHRKMT2A | |
| SCHEMBL26543475 | 0.75 | TAS1R3 (0.47) | KDM4E | |
| SCHEMBL24197308 | 0.74 | KDM4E (0.49) | KDM4EMEN1TSHRKMT2A | |
| SCHEMBL19146388 | 0.74 | KDM4E (0.49) | KDM4EMEN1TSHRKMT2A | |
| SCHEMBL21376542 | 0.74 | KDM4E (0.49) | KDM4EMEN1TSHRKMT2A | |
| SCHEMBL26152399 | 0.74 | KDM4E (0.48) | KDM4EMEN1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | KDM4E 4116/4885MEN1 1419/4885TSHR 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.